- Previous Close
28.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 28.00 - Volume
0 - Avg. Volume
171 - Market Cap (intraday)
-- - Beta (5Y Monthly) 1.29
- PE Ratio (TTM)
0.11 - EPS (TTM)
1.35 - Earnings Date Nov 14, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO brand, and cosmetics under the brand M1 SELECT, as well as supplies third party-products. It serves clinics, pharmacies, wholesalers, and medical test centers. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.
www.haemato.ag76
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0VZ7.L
View MorePerformance Overview: 0VZ7.L
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0VZ7.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0VZ7.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
3.68%
Return on Assets (ttm)
3.22%
Return on Equity (ttm)
6.52%
Revenue (ttm)
260.81M
Net Income Avi to Common (ttm)
9.61M
Diluted EPS (ttm)
1.35
Balance Sheet and Cash Flow
Total Cash (mrq)
13.94M
Total Debt/Equity (mrq)
2.07%
Levered Free Cash Flow (ttm)
4.64M